HIFU-Prostate
HIFU-Prostate website was set up to provide patients with useful information relating to prostate cancer treatments and particularly on HIFU treatment. The information displayed on HIFU-Prostate website is targeting general public and physicians seeking information on prostate cancer and HIFU technology.The information available on HIFU-Prostate website is not a substitute to professional diagnosis and to discussions with your physician and/or urologist.
Funding
HIFU-Prostate is entirelly funding by EDAP TMS company. EDAP TMS is established at 4, rue du Dauphiné, 69120 Vaulx-en-Velin, France.
Advertising
There is no advertising in HIFU-Prostate website.
The Company
Global leader in therapeutic ultrasound for now 40 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes minimally invasive and innovative medical devices using ultrasound technology.
Actively operating worldwide via an extensive network of subsidiaries, corporate offices, and distribution partners, EDAP TMS is currently marketing two ranges of urology products dedicated to localized prostate cancer and urinary stones. EDAP TMS is also developing its innovative technologies to expand applications beyond urology
By combining the latest technologies in imaging and treatment modalities, EDAP TMS introduced the Focal One® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing Ablatherm® HIFU device.
As a pioneer and key player in the field of extracorporeal lithotripsy (ESWL), EDAP TMS exclusively utilized the latest generation of shock wave source in its Sonolith® range of ESWL systems.
Development partnerships
EDAP TMS is partnering with renowned medical research institutions (basic research and clinical research) to develop its medical devices and its large patent portfolio based on its innovative technologies. Fundamental ultrasound research is leaded by the French National Institute for Health and Medical Research (INSERM), development, manufacturing and marketing is leaded by EDAP TMS and clinical validation is leaded by University hospitals (Edouard Herriot Hospital in Lyon). This partnership is focused on innovation to develop current and future medical applications that meet surgeons’ needs and patient’s quality of life preservation.